Condition: Pruritus · Atopic Dermatitis · Sponsor: Cara Therapeutics, Inc.
This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Cara Therapeutics Study Site | Scottsdale, Arizona, United States | — |
| Cara Therapeutics Study Site | Fort Smith, Arkansas, United States | — |
| Cara Therapeutics Study Site | Rogers, Arkansas, United States | — |
| Cara Therapeutics Study Site | Fountain Valley, California, United States | — |
| Cara Therapeutics Study Site | Lomita, California, United States | — |
| Cara Therapeutics Study Site | Los Angeles, California, United States | — |
| Cara Therapeutics Study Site | Redwood City, California, United States | — |
| Cara Therapeutics Study Site | Sacramento, California, United States | — |
| Cara Therapeutics Study Site | San Diego, California, United States | — |
| Cara Therapeutics Study Site 2 | Santa Monica, California, United States | — |
| Cara Therapeutics Study Site | Santa Monica, California, United States | — |
| Cara Therapeutics Study Site | Valencia, California, United States | — |
+ 49 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.